开云app官网登录入口网页版-官方正版

#色素#

654篇内容 | 4831人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1680824, encodeId=daff16808241b, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究, objectType=article, longId=736665, objectId=88b3e36665f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88b3e36665f7, replyNumber=0, likeNumber=81, createdTime=2023-06-21, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88b3e36665f7, moduleTitle=Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=88b3e36665f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680825, encodeId=32f216808250e, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, objectType=article, longId=737793, objectId=5560e37793d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5560e37793d5, replyNumber=0, likeNumber=150, createdTime=2023-07-13, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5560e37793d5, moduleTitle=J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5560e37793d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680811, encodeId=94981680811d9, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Movement disorders：非典型帕金森病，黑质中神经黑色素变化有何特点？, objectType=article, longId=729763, objectId=8049e297639f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8049e297639f, replyNumber=0, likeNumber=79, createdTime=2022-12-02, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8049e297639f, moduleTitle=Movement disorders：非典型帕金森病，黑质中神经黑色素变化有何特点？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8049e297639f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680821, encodeId=2add1680821ff, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=肤色的决定因素—黑色素, objectType=article, longId=735557, objectId=69eae355578d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69eae355578d, replyNumber=0, likeNumber=114, createdTime=2023-07-22, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69eae355578d, moduleTitle=肤色的决定因素—黑色素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=69eae355578d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680807, encodeId=6baa168080ea5, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, objectType=article, longId=728227, objectId=6d23e28227bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d23e28227bf, replyNumber=0, likeNumber=79, createdTime=2022-08-21, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d23e28227bf, moduleTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6d23e28227bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680829, encodeId=d074168082925, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=这些面部色素性增生物一定要警惕！, objectType=article, longId=738606, objectId=0e2be38606bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e2be38606bd, replyNumber=0, likeNumber=100, createdTime=2023-06-20, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e2be38606bd, moduleTitle=这些面部色素性增生物一定要警惕！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e2be38606bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680830, encodeId=406c1680830ab, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=JAMA Dermatol：低剂量甲氨蝶呤暴露与黑色素瘤的相关性，系统综述和荟萃分析, objectType=article, longId=739238, objectId=6a95e39238e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a95e39238e9, replyNumber=0, likeNumber=86, createdTime=2023-05-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a95e39238e9, moduleTitle=JAMA Dermatol：低剂量甲氨蝶呤暴露与黑色素瘤的相关性，系统综述和荟萃分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a95e39238e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680800, encodeId=7efa1680800a8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=色素痣有哪些分类？如何治疗？, objectType=article, longId=724535, objectId=1ea3e2453508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ea3e2453508, replyNumber=0, likeNumber=88, createdTime=2022-07-21, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ea3e2453508, moduleTitle=色素痣有哪些分类？如何治疗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1ea3e2453508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680801, encodeId=c3a4168080116, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, objectType=article, longId=726015, objectId=0c7fe2601525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7fe2601525, replyNumber=0, likeNumber=89, createdTime=2022-07-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7fe2601525, moduleTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c7fe2601525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680831, encodeId=4fe71680831a7, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Adv Ther：计划行为理论在黑色素瘤切除患者坚持辅助治疗中的应用, objectType=article, longId=739109, objectId=f048e391092c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f048e391092c, replyNumber=0, likeNumber=114, createdTime=2023-07-13, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f048e391092c, moduleTitle=Adv Ther：计划行为理论在黑色素瘤切除患者坚持辅助治疗中的应用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f048e391092c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680817, encodeId=5d60168081e4c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=黑色素细胞性皮肤肿瘤的治疗研究进展, objectType=article, longId=732137, objectId=c77fe32137e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77fe32137e8, replyNumber=0, likeNumber=115, createdTime=2022-11-18, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77fe32137e8, moduleTitle=黑色素细胞性皮肤肿瘤的治疗研究进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c77fe32137e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680808, encodeId=1acd16808082e, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, objectType=article, longId=728275, objectId=a347e2827567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a347e2827567, replyNumber=0, likeNumber=130, createdTime=2023-04-10, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a347e2827567, moduleTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a347e2827567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680826, encodeId=08461680826a3, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤, objectType=article, longId=737805, objectId=47e8e378058e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e8e378058e, replyNumber=0, likeNumber=90, createdTime=2022-10-19, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e8e378058e, moduleTitle=Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=47e8e378058e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680791, encodeId=bc001680e913e, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=115, createdTime=2022-04-05, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680805, encodeId=2854168080574, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=2022 ASCO：免疫治疗时代，原发灶不明的恶性黑色素瘤患者生存率得到改善, objectType=article, longId=728231, objectId=69a9e28231d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a9e28231d1, replyNumber=0, likeNumber=0, createdTime=2022-10-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a9e28231d1, moduleTitle=2022 ASCO：免疫治疗时代，原发灶不明的恶性黑色素瘤患者生存率得到改善, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=69a9e28231d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680792, encodeId=b0e21680e92e4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Int J Cancer：色素痣的数量与癌症风险有关吗？, objectType=article, longId=300818, objectId=9081300818e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9081300818e7, replyNumber=0, likeNumber=88, createdTime=2022-04-03, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9081300818e7, moduleTitle=Int J Cancer：色素痣的数量与癌症风险有关吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9081300818e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680782, encodeId=b6391680e8200, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, objectType=article, longId=293979, objectId=c08c2939e93e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c08c2939e93e, replyNumber=0, likeNumber=116, createdTime=2022-06-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c08c2939e93e, moduleTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c08c2939e93e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680816, encodeId=42cf168081674, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=86, createdTime=2023-04-30, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680796, encodeId=88be1680e96ac, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, objectType=article, longId=302063, objectId=7e953020633b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e953020633b, replyNumber=0, likeNumber=91, createdTime=2022-05-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e953020633b, moduleTitle=BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7e953020633b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680819, encodeId=db851680819ab, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究, objectType=article, longId=733988, objectId=09ebe339886f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09ebe339886f, replyNumber=0, likeNumber=77, createdTime=2023-06-03, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09ebe339886f, moduleTitle=Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=09ebe339886f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

色素

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#色素#

Cancer Sci：T-VEC治疗日本晚期黑色素瘤患者的安全性和有效性-I期研究

2023-06-21

sunylz (审核中...)

前往app查看评论内容

#色素#

J Clin Oncol：Talimogene Laherparepvec联合派姆单抗治疗晚期黑色素瘤

2023-07-13

sunylz (审核中...)

前往app查看评论内容

#色素#

Movement disorders：非典型帕金森病，黑质中神经黑色素变化有何特点？

2022-12-02

sunylz (审核中...)

前往app查看评论内容

#色素#

肤色的决定因素—黑色素

2023-07-22

sunylz (审核中...)

前往app查看评论内容

#色素#

ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者

2022-08-21

sunylz (审核中...)

前往app查看评论内容

#色素#

这些面部色素性增生物一定要警惕！

2023-06-20

sunylz (审核中...)

前往app查看评论内容

#色素#

JAMA Dermatol：低剂量甲氨蝶呤暴露与黑色素瘤的相关性，系统综述和荟萃分析

2023-05-15

sunylz (审核中...)

前往app查看评论内容

#色素#

色素痣有哪些分类？如何治疗？

2022-07-21

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）

2022-07-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Adv Ther：计划行为理论在黑色素瘤切除患者坚持辅助治疗中的应用

2023-07-13

sunylz (审核中...)

前往app查看评论内容

#色素#

黑色素细胞性皮肤肿瘤的治疗研究进展

2022-11-18

sunylz (审核中...)

前往app查看评论内容

#色素#

ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素

2023-04-10

一叶知秋 (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：阿特珠单抗联合贝伐单抗治疗晚期黏膜黑色素瘤

2022-10-19

sunylz (审核中...)

前往app查看评论内容

#色素#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-04-05

sunylz (审核中...)

前往app查看评论内容

#色素#

2022 ASCO：免疫治疗时代，原发灶不明的恶性黑色素瘤患者生存率得到改善

2022-10-15

sunylz (审核中...)

前往app查看评论内容

#色素#

Int J Cancer：色素痣的数量与癌症风险有关吗？

2022-04-03

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征

2022-06-24

sunylz (审核中...)

前往app查看评论内容

#色素#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2023-04-30

sunylz (审核中...)

前往app查看评论内容

#色素#

BJH：慢性淋巴细胞白血病对黑色素瘤结局的影响：一项回顾性病例对照研究

2022-05-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Melanoma Res：阿帕替尼联合替莫唑胺治疗免疫治疗失败后的晚期黑色素瘤患者的II期研究

2023-06-03

科室
- - 订阅+
  - 更多科室
工具
服务